Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Directorate Change

16 Dec 2016 14:44

RNS Number : 1204S
Circassia Pharmaceuticals Plc
16 December 2016
 

Circassia Pharmaceuticals plc

 

Non-Executive Director Retirement

 

 

Oxford, UK - 16 December 2016: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on allergy and asthma, today announces the retirement of Cathrin Petty from its Board, following nearly seven years as a Non-Executive Director.

 

Dr Francesco Granata, Circassia's Chairman, commented: "On behalf of the Board, I would like to thank Cathrin for her significant contribution to the Company over many years, and we wish her well in her new role as Head of European Healthcare at CVC Capital Partners."

 

Commenting on her retirement, Cathrin Petty said: "I firmly believe that Circassia is well positioned to achieve its ambition to become a self-sustaining, world-class specialty biopharmaceutical company. Unfortunately, the time commitments of my new role preclude me from contributing further as a Director, but I will continue to follow Circassia's progress keenly."

 

-Ends-

 

For further information, please contact:

 

Circassia

Steve Harris, Chief Executive Officer

Julien Cotta, Chief Financial Officer

Rob Budge, Corporate Communications

Tel: +44 (0)1865 405 560

FTI Consulting

Ben Atwell / Simon Conway / Mo Noonan

Tel: +44 (0) 20 3727 1000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGPCPUPQGCQ
Date   Source Headline
8th Jul 20195:02 pmRNSHolding(s) in Company
5th Jul 201912:07 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:55 pmRNSHolding(s) in Company
1st Jul 20194:55 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20194:57 pmRNSBlock Listing Application
17th Jun 20194:35 pmRNSPrice Monitoring Extension
7th Jun 20196:00 pmRNSHolding(s) in Company
7th Jun 20194:18 pmRNSResult of AGM
6th Jun 20196:23 pmRNSHolding(s) in Company
6th Jun 20194:11 pmRNSHolding(s) in Company
31st May 20197:00 amRNSTotal Voting Rights
28th May 20195:58 pmRNSHolding(s) in Company
28th May 20195:56 pmRNSHolding(s) in Company
21st May 20199:05 amRNSHolding(s) in Company
14th May 20194:24 pmRNSAnnual report and notice of AGM
8th May 20197:00 amRNSPublication of Tudorza Phase IV ASCENT in JAMA
3rd May 20192:18 pmRNSIssue of Equity
1st May 20197:00 amRNSFinal Results
30th Apr 20197:00 amRNSTotal Voting Rights
15th Apr 201911:55 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSFDA approval of Duaklir for treatment of COPD
29th Mar 20194:40 pmRNSSecond Price Monitoring Extn
29th Mar 20194:35 pmRNSPrice Monitoring Extension
29th Mar 20193:58 pmRNSFDA website posts Duaklir NDA approval
29th Mar 20193:34 pmRNSCircassia announces FDA approval of Tudorza sNDA
29th Mar 20197:00 amRNSTotal Voting Rights
5th Mar 20194:53 pmRNSHolding(s) in Company
4th Mar 20194:04 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSTotal Voting Rights
11th Feb 20195:17 pmRNSHolding(s) in Company
8th Feb 20199:00 amRNSNotice of Results
6th Feb 20194:44 pmRNSHolding(s) in Company
6th Feb 20197:00 amRNSHolding(s) in Company
4th Feb 20195:57 pmRNSHolding(s) in Company
4th Feb 20198:06 amRNSSuccessful FDA Presubmission Meeting for AirNOvent
4th Feb 20198:06 amRNSAdmission to AIM
1st Feb 20194:36 pmRNSPrice Monitoring Extension
1st Feb 20194:03 pmRNSHolding(s) in Company
31st Jan 20197:00 amRNSTotal Voting Rights
30th Jan 20195:30 pmRNSCircassia Pharmaceuticals
30th Jan 20194:41 pmRNSSecond Price Monitoring Extn
30th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20193:30 pmRNSHolding(s) in Company
28th Jan 20193:30 pmRNSHolding(s) in Company
25th Jan 201911:49 amRNSHolding(s) in Company
24th Jan 20197:00 amRNSCommercial rights acquired from AIT Therapeutics
18th Jan 20192:22 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.